[ad_1]
Turkish scientists living in Germany on the coronavirus vaccine Prof. Dr. The discovery made by Uğur Şahin and Özlem Türeci gave the whole world great hope. After the studies that gained the appreciation of the world in the vaccine, another good news arrived from the drug against the coronavirus.
KORONA’S FIRST DRUG PRODUCED
Turkish scientists first found the vaccine, then developed a test, and now they found the corona drug. In this context, Prof. Dr. Formycon company produced the first crown drug with the work of İbrahim Benter.
“COVID-19 HAS BEEN TREATED”
Speaking with Kanal D Haber about the drug, Prof. Dr. İbrahim Benter, “Kovid-19 treatment has been found.” made the explanation.
Benter used the following statements in the rest of his speech: “This drug will be able to treat those who are sick, that is, people who have received this vaccine or have not received it will be able to prevent the damage of the virus in the body through the use of this drug. This drug will be very effective in the short and long term term”.
“IT WILL BRING THE END OF THE DRUG PANDEM”
“Even if the virus mutates and changes and provides resistance to vaccines, with this approach we can cure these diseases. It is sooner to say something about its side effects and dosage, but we hope it is a drug that has other benefits without many side effects. Corona treatment has been found. I believe this will bring the end of the pandemic now.
“THE DRUG CLOSES THE DOORS OF THE CORONAVIRUS”
The developed drug completely prevents cells from becoming infected with this virus and uses the ACE2 receptors that the virus uses to enter the body. The drug is effective exactly where the ACE2 antibody fusion protein comes from, which binds effectively to coronaviruses. In a sense, it closes the arrival doors of the coronavirus. The drug was announced to be effective against the mutated version of the virus as well. Carsten Brockmeyer, Formycon CEO, said in a statement that people who are now hospitalized have another treatment option.
“THIS WAY WILL AVOID FUTURE CORONAVIRUS OUTBREAKS”
Brockmeyer said the drug is the solution at this stage: “Antibodies target very specific regions on the surface of the SARS CoV-2 virus. However, a small mutation of the virus is enough to inactivate them. With this drug, we block the gateway that the virus uses to enter cells. ” “It also provides maximum protection against mutations. This will prevent future coronavirus outbreaks,” he said.
EARLY DATE 2022
The company that developed the drug announced that it has contacted the US drug approval center and the European Union approval center and that the process has been carried out for speedy approval. However, even the fastest approval indicates that they will be able to launch the drug only in early 2022.
WHO IS İBRAHİM BENTER?
Prof. Dr. İbrahim F. Benter was born in 1962 in Nicosia. Studying at Turkish Maarif College, Prof. Dr. İbrahim Benter was in the US between 1980 and 2000. He graduated from the University of Florida School of Chemistry in 1985. He studied at New York School of Medicine and received a doctorate from the Ohio State University School of Medicine in 1991. The Cleveland Clinic Foundation also specialized in the Department of Brain and Vascular. Working as a researcher in the Department of Hypertension Research at Wake Forest University School of Medicine, Prof. Dr. İbrahim Benter worked first as an assistant professor and then as an associate professor in the School of Medicine and Eye School of the University of Tennessee at Memphis in 1994.
He has received numerous awards in education and research. His most important invention, a hormone known as angiotensin- (1-7), is being tested for cancer, hypertension, and heart disease. In 2001-2012, he worked as a professor in the Department of Pharmacology at the Kuwait University School of Medicine, head of the department and many administrative offices. He has been with the University of Oxford since September 2012. He worked with the Nobel laureate Professor Sir John Vane and Professor Sir Martin Evans. The research topic is the treatment of heart and vascular problems in patients with hypertension and diabetes.
